MHRA consulting for ‘no deal’ Brexit
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is consulting on proposed changes to the way it would regulate medicinal products in the country in the event of a ‘no deal’ UK exit from the European Union (EU) on 29 March 2019.
You may also be interested in...
Supply Of 'Important' OTCs From EU Prioritized In Event Of No Deal Brexit
In preparation for a possible no deal Brexit, the UK government is prioritizing supply from the EU those OTC medicines deemed "important for the management of specific health conditions." The Department of Health and Social Care says it is continuing to work closely with OTC manufacturers and suppliers to prepare for Brexit.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.